Company: EDSA
Filing Date: 2025-03-11
Form Type: 424B3
Source: 0001171843-25-001403
Chunk: 14

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-11
Form: 424B3
Chunk 14
---
 from time
to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act amending the list of Selling Shareholders to include the pledgee, transferee or other successors in interest as Selling Shareholders
under this prospectus. The Selling Shareholders also may transfer the Shares or Conversion Shares in other circumstances, in which case
the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

In connection with the sale of the Shares,
Conversion Shares or interests therein, the Selling Shareholders may enter into hedging transactions with broker- dealers or other financial
institutions, which may in turn engage in short sales of the Shares or the Conversion Shares in the course of hedging the positions they
assume. The Selling Shareholders may also sell the Shares or the Conversion Shares short and deliver these securities to close out their
short positions, or loan or pledge the Shares or the Conversion Shares to broker-dealers that in turn may sell these securities. The Selling
Shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one
or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this
prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or
amended to reflect such transaction).

The aggregate proceeds to the Selling
Shareholders from the sale of the Shares or the Conversion Shares offered by them will be the purchase price of the Shares or the Conversion
Shares less discounts or commissions, if any. Each of the Selling Shareholders reserves the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of the Shares or the Conversion Shares to be made directly or
through agents. We will not receive any of the proceeds from this offering.

| 12 |

The Selling Shareholders and any underwriters,
broker-dealers or agents that participate in the sale of the Shares, the Conversion Shares or interests therein may be “underwriters”
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of
the Shares or the Conversion Shares may be underwriting discounts and commissions under the Securities Act. Selling Shareholders who are
“underwriters” within the